KR101409706B1 - 만성 폐쇄성 폐질환의 치료를 위한 방법 및 조성물 - Google Patents

만성 폐쇄성 폐질환의 치료를 위한 방법 및 조성물 Download PDF

Info

Publication number
KR101409706B1
KR101409706B1 KR1020087023221A KR20087023221A KR101409706B1 KR 101409706 B1 KR101409706 B1 KR 101409706B1 KR 1020087023221 A KR1020087023221 A KR 1020087023221A KR 20087023221 A KR20087023221 A KR 20087023221A KR 101409706 B1 KR101409706 B1 KR 101409706B1
Authority
KR
South Korea
Prior art keywords
ether
chronic obstructive
obstructive pulmonary
pulmonary disease
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087023221A
Other languages
English (en)
Korean (ko)
Other versions
KR20080104024A (ko
Inventor
류지 우에노
사치코 구노
Original Assignee
수캄포 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 수캄포 아게 filed Critical 수캄포 아게
Publication of KR20080104024A publication Critical patent/KR20080104024A/ko
Application granted granted Critical
Publication of KR101409706B1 publication Critical patent/KR101409706B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020087023221A 2006-02-28 2007-02-27 만성 폐쇄성 폐질환의 치료를 위한 방법 및 조성물 Expired - Fee Related KR101409706B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77694306P 2006-02-28 2006-02-28
US60/776,943 2006-02-28
PCT/JP2007/054127 WO2007102446A2 (en) 2006-02-28 2007-02-27 Method and composition for treating chronic obstructive pulmonary disease

Publications (2)

Publication Number Publication Date
KR20080104024A KR20080104024A (ko) 2008-11-28
KR101409706B1 true KR101409706B1 (ko) 2014-06-20

Family

ID=38462529

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087023221A Expired - Fee Related KR101409706B1 (ko) 2006-02-28 2007-02-27 만성 폐쇄성 폐질환의 치료를 위한 방법 및 조성물

Country Status (13)

Country Link
US (1) US20070203228A1 (enExample)
EP (1) EP1988905B1 (enExample)
JP (2) JP5377970B2 (enExample)
KR (1) KR101409706B1 (enExample)
CN (1) CN101432002B (enExample)
AR (1) AR059636A1 (enExample)
AU (1) AU2007223469B2 (enExample)
BR (1) BRPI0708362A2 (enExample)
CA (1) CA2642744C (enExample)
MX (1) MX2008011148A (enExample)
NZ (1) NZ571092A (enExample)
TW (1) TWI422368B (enExample)
WO (1) WO2007102446A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0708362A2 (pt) * 2006-02-28 2011-05-24 Sucampo Ag método e composição para o tratamento de doença pulmonar obstrutiva crÈnica
WO2011072383A1 (en) * 2009-12-18 2011-06-23 Apotex Pharmachem Inc. Processes for the purification of lubiprostone
BR112013026644A2 (pt) * 2011-04-19 2016-12-27 Sucampo Ag método para a modulação da atividade de citocina
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739161A (en) * 1994-06-03 1998-04-14 R-Tech Ueno, Ltd. Agent for treating hepto.biliary diseases
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2597649B2 (ja) * 1988-05-11 1997-04-09 株式会社上野製薬応用研究所 気管・気管支拡張剤
US5362751A (en) * 1988-05-11 1994-11-08 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Tracheobronchodilator using 16-substituted PGEs
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
JPH0791192B2 (ja) * 1989-11-22 1995-10-04 株式会社上野製薬応用研究所 ガス交換機能不全処置剤
PT978284E (pt) * 1997-11-28 2008-10-07 Sucampo Ag Utilização de compostos 15-ceto-prostaglandina-e como antagonistas da endotelina
ATE433754T1 (de) * 2000-04-06 2009-07-15 Sucampo Ag Gallensäurefördernde zusammensetzung für lebertransplantation welche ein 15-keto prostaglandin enthält
CA2458471C (en) * 2001-08-31 2012-07-31 Sucampo Ag Prostaglandin analogs as chloride channel opener
JP5294559B2 (ja) * 2003-07-03 2013-09-18 スキャンポ・アーゲー クロライドチャンネルオープナーとしてプロスタグランジンアナログを含む腸溶性組成物
BRPI0708362A2 (pt) * 2006-02-28 2011-05-24 Sucampo Ag método e composição para o tratamento de doença pulmonar obstrutiva crÈnica
BR112013026644A2 (pt) * 2011-04-19 2016-12-27 Sucampo Ag método para a modulação da atividade de citocina

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
US5739161A (en) * 1994-06-03 1998-04-14 R-Tech Ueno, Ltd. Agent for treating hepto.biliary diseases

Also Published As

Publication number Publication date
CN101432002B (zh) 2012-04-04
EP1988905B1 (en) 2014-06-04
TW200800161A (en) 2008-01-01
NZ571092A (en) 2010-11-26
JP2013209429A (ja) 2013-10-10
JP2009528259A (ja) 2009-08-06
EP1988905A2 (en) 2008-11-12
AU2007223469B2 (en) 2012-06-07
KR20080104024A (ko) 2008-11-28
CA2642744A1 (en) 2007-09-13
MX2008011148A (es) 2008-09-08
BRPI0708362A2 (pt) 2011-05-24
CN101432002A (zh) 2009-05-13
WO2007102446A3 (en) 2008-04-03
TWI422368B (zh) 2014-01-11
AR059636A1 (es) 2008-04-16
AU2007223469A1 (en) 2007-09-13
JP5377970B2 (ja) 2013-12-25
US20070203228A1 (en) 2007-08-30
CA2642744C (en) 2015-02-24
WO2007102446A2 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
EP0345951B1 (en) Tracheobronchodilator
KR101409706B1 (ko) 만성 폐쇄성 폐질환의 치료를 위한 방법 및 조성물
US8530519B2 (en) Method for promoting upper gastrointestinal bicarbonate secretion
JPH0571568B2 (enExample)
AU2001239551B8 (en) Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
JPH0770054A (ja) 生化学的拮抗および疾患処置剤
CA2030344C (en) Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
EP0454429B1 (en) Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases
JP4091132B2 (ja) 門脈圧亢進抑制剤
JP2609479B2 (ja) カリウム排泄剤
JPWO1999018968A1 (ja) 門脈圧亢進抑制剤
JP2515442B2 (ja) 膵臓疾患処置剤
JPH03218315A (ja) ガス交換機能不全処置剤
CA2022081C (en) Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
JPH03163024A (ja) 高脂質血症処置・血中脂質成分低下剤
JP2515442C (enExample)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170613

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170613